In This Section
Dr. Lynch maintains a dynamic program that involves clinical, translational, and basic science research efforts focused on the rare disease Friedreich ataxia.
Dr. Lynch maintains a dynamic program focused on the rare disease Friedreich's ataxia (FA), a progressive neurogenetic condition found in approximately one in 50,000 people worldwide.
More specifically, the research led by Dr. Lynch spans clinical, translational, and basic science research efforts on FA that include conducting double-blind clinical trials, identifying biomarkers, and leading mechanistic studies in animal and cellular models of FA.
The research conducted by Dr. Lynch and his lab team have led to a greater understanding of the metabolic dysfunction underlying FA. Their work has led to the creation of a patient database as well as a pipeline of more than 20 drug candidates that represent potential new therapies. Dr. Lynch is currently working with pharmaceutical industry partners to develop drug candidates as well as biomarkers for FA.
Education and Training
BS, Yale College (Molecular Biophysics and Biochemistry), 1981
MD, Johns Hopkins University, 1988
PhD, Johns Hopkins University (Neuroscience), 1988
Titles and Academic Titles
Professor of Neurology
Pfizer Pharmaceutical Postdoctoral Fellowship, Pfizer Pharmaceuticals, 1992
Teaching Award, Neuroscience 100, University of Pennsylvania School of Medicine, 1996, 1997
Paul Beeson Scholars Award, American Federation for Aging Research, 1999
Top Docs in Philadelphia, Philadelphia Magazine, 2002
Best Doctors in America, Best Doctors, 2005
Friedreich Ataxia Research Alliance Service Award, Friedreich Ataxia Research Alliance, 2008
Best Doctors for Women, Philadelphia Life Magazine, 2013